SCHEMBL2470538

SCHEMBL2470538

C/C=C\CCCCCCC(C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.50
ACE2 Q9BYF1 1/20 0.47
CYP1A2 P05177 2/20 0.47
BLM P54132 3/20 0.46
GABRR1 P24046 2/20 0.42
TBXAS1 P24557 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
TERT O14746 3/20 0.40
PTPN1 P18031 3/20 0.40
MAPT P10636 2/20 0.40
HSD17B10 Q99714 2/20 0.40
FABP4 P15090 2/20 0.40
F7 P08709 2/20 0.40
F3 P13726 2/20 0.40
PPARG P37231 2/20 0.40
PPARD Q03181 2/20 0.40
PPARA Q07869 2/20 0.40
GMNN O75496 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8694153 1.00 LTA4H (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL8694155 1.00 LTA4H (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL1716729 1.00 LTA4H (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL1716727 1.00 LTA4H (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL21595289 0.98 LTA4H (0.52) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL21595291 0.98 LTA4H (0.52) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL7253734 0.92 CYP1A2 (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL7253732 0.92 CYP1A2 (0.50) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL414072 0.90 ACE2 (0.52) LTA4HACE2CYP1A2BLMGABRR1
SCHEMBL31189197 0.90 ALDH1A1 (0.47) LTA4HBLMFFAR1FFAR4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10011554-B2 Alpha-branched alkenoic acids and the use of alpha-branched alkanoic and alkenoic acids as a fragrance Givaudan, S.A. (CH) 2018-07-03 US disclosed
US-20170327452-A1 ALPHA-BRANCHED ALKENOIC ACIDS AND THE USE OF ALPHA-BRANCHED ALKANOIC AND ALKENOIC ACIDS AS A FRAGRANCE GIVAUDAN S.A. (CH) 2017-11-16 US disclosed
US-9745245-B2 Alpha-branched alkenoic acids and the use of alpha-branched alkanoic and alkenoic acids as a fragrance GIVAUDAN S.A. (CH) 2017-08-29 US disclosed
EP-2370391-B1 ALPHA-BRANCHED ALKENOIC ACIDS AND THE USE OF ALPHA-BRANCHED ALKANOIC AND ALKENOIC ACIDS AS A FRAGRANCE GIVAUDAN SA (CH) 2014-02-12 EP disclosed
US-20110263725-A1 Alpha-branched Alkenoic Acids and the Use of Alpha-branched Alkanoic and Alkenoic Acids as a Fragrance GIVAUDAN SA (CH) 2011-10-27 US disclosed
EP-2370391-A1 ALPHA-BRANCHED ALKENOIC ACIDS AND THE USE OF ALPHA-BRANCHED ALKANOIC AND ALKENOIC ACIDS AS A FRAGRANCE Givaudan SA (CH) 2011-10-05 EP disclosed
WO-2010063133-A1 ALPHA-BRANCHED ALKENOIC ACIDS AND THE USE OF ALPHA-BRANCHED ALKANOIC AND ALKENOIC ACIDS AS A FRAGRANCE GIVAUDAN SA (CH) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011554-B2 Alpha-branched alkenoic acids and the use of alpha-branched alkanoic and alkenoic acids as a fragrance FASN, ELOVL1, ACOX1 LTA4H 46/4885ACE2 1809/4885CYP1A2 206/4885
US-20110263725-A1 Alpha-branched Alkenoic Acids and the Use of Alpha-branched Alkanoic and Alkenoic Acids as a Fragrance FASN, ELOVL1, ACOX1 LTA4H 46/4885ACE2 1809/4885CYP1A2 206/4885
US-20170327452-A1 ALPHA-BRANCHED ALKENOIC ACIDS AND THE USE OF ALPHA-BRANCHED ALKANOIC AND ALKENOIC ACIDS AS A FRAGRANCE FASN, ELOVL1, ACOX1 LTA4H 46/4885ACE2 1809/4885CYP1A2 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.